Last reviewed · How we verify
NCT06161051
Treatment Patterns and Real-World Clinical Outcomes in Patients With Advanced NSCLC and MET Exon 14 Skipping Mutation in the United States
trial in Advanced Non-small Cell Lung Cancer and MET Exon 14 Skipping Mutation in 287 participants. Completed in 7 December 2022.
2 November 2022
Quick facts
| Lead sponsor | Novartis Pharmaceuticals |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 287 |
| Start date | 3 October 2022 |
| Primary completion | 2 November 2022 |
| Estimated completion | 7 December 2022 |
| Sites | 1 location across United States |
Conditions studied
- Advanced Non-small Cell Lung Cancer and MET Exon 14 Skipping Mutation — all drugs for Advanced Non-small Cell Lung Cancer and MET Exon 14 Skipping Mutation →
Sponsor
Novartis Pharmaceuticals — full company profile →
Who can join
18 and older, any sex, with Advanced Non-small Cell Lung Cancer and MET Exon 14 Skipping Mutation. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This was a retrospective, noninterventional cohort study of patients with a confirmed diagnosis of advanced non-small cell lung cancer (aNSCLC) with MET exon 14 skipping mutation who received treatment with capmatinib, immunotherapy (IO), or chemotherapy (CT) in real-world practice settings. Data abstraction was performed by the participating physician.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Targeting MET in non-small cell lung cancer brain metastases: from molecular mechanism to precision therapy.
Wang X, Chi Y, Mu F, Mao H, et al · · 2026 · PMID 41981677 · DOI 10.1186/s12967-026-08077-2
Verify or expand the search:
- PubMed search for NCT06161051
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Novartis Pharmaceuticals trials
Trials by the same sponsor.
- NCT07498335 — Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary · Phase 3 · not yet recruiting
- NCT07489573 — Study of Efficacy and Safety of Secukinumab in Chinese Adult Patients With Moderate to Severe Hidradenitis Suppurativa · Phase 4 · not yet recruiting
- NCT07484269 — PULSE Registry: for Patients Receiving Lutetium (177Lu) Vipivotide Tetraxetan · not yet recruiting
- NCT07416162 — A Study of Iptacopan in Korean Patients With Paroxysmal Nocturnal Hemoglobinuria or C3 Glomerulopathy · not yet recruiting
- NCT07387926 — Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+ · Phase 1, PHASE2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06161051 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Novartis Pharmaceuticals
- Last refreshed: 7 December 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06161051.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing